EUVIMEDEUVIMED entdecken
Übersichtsarbeit

PET Imaging of Breast Cancer: Current Applications and Future Directions

Christine E Edmonds iD, Sophia R O'Brien iD, Elizabeth S McDonald, David A Mankoff, Austin R Pantel

Journal of Breast Imaging · 2024

DOI: 10.1093/jbi/wbae053 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Breast Imaging, 2024. Verfasst von Christine E Edmonds und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA. Hauptthemen laut MEDLINE: Breast Neoplasms, Positron-Emission Tomography, Fluorodeoxyglucose F18. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 153 Literaturangaben. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

As molecular imaging use expands for patients with breast cancer, it is important for breast radiologists to have a basic understanding of molecular imaging, including PET. Although breast radiologists may not directly interpret such studies, basic knowledge of molecular imaging will enable the radiologist to better direct diagnostic workup of patients as well as discuss diagnostic imaging with the patient and other treating physicians. Several new tracers are now available to complement imaging glucose metabolism with FDG. Because it provides a noninvasive assessment of disease status across the whole body, PET offers specific advantages over tissue-based assays. Paired with targeted therapy, molecular imaging has the potential to guide personalized treatment of breast cancer, including guiding dosing during drug trials as well as predicting and assessing clinical response. This review discusses the current established applications of FDG, which remains the most widely used PET radiotracer for malignancy, including breast cancer, and highlights potential areas for expanded use based on recent research. It also summarizes research to date on the U.S. Food and Drug Administration (FDA)–approved PET tracer 16α-18F-fluoro-17β-estradiol (FES), which targets ER, including the current guidelines from the Society of Nuclear Medicine and Molecular Imaging on the appropriate use of FES-PET/CT for breast cancer as well as areas of active investigation for other potential applications. Finally, the review highlights several of the most promising novel PET tracers that are poised for clinical translation in the near future.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsPositron-Emission TomographyFluorodeoxyglucose F18HumansFemaleRadiopharmaceuticalsMolecular Imaging

Stichwörter der Autor:innen

breast imaging quality and outcomesbreast nuclear medicinebreast pathology

Substanzen

Fluorodeoxyglucose F18Radiopharmaceuticals

Autor:innen und Institutionen

  • Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.

ORCID-Profile: Christine E Edmonds, Sophia R O'Brien

Förderung

  • NCI NIH HHS

Zitieren

APA

Edmonds, C. E., O'Brien, S. R., McDonald, E. S., Mankoff, D. A., & Pantel, A. R. (2024). PET Imaging of Breast Cancer: Current Applications and Future Directions. Journal of Breast Imaging. https://doi.org/10.1093/jbi/wbae053

Vancouver

Edmonds CE, O'Brien SR, McDonald ES, Mankoff DA, Pantel AR. PET Imaging of Breast Cancer: Current Applications and Future Directions. Journal of Breast Imaging. 2024. doi:10.1093/jbi/wbae053

BibTeX
@article{Edmonds2024,
  author = {Edmonds, Christine E and O'Brien, Sophia R and McDonald, Elizabeth S and Mankoff, David A and Pantel, Austin R},
  title = {PET Imaging of Breast Cancer: Current Applications and Future Directions},
  journal = {Journal of Breast Imaging},
  year = {2024},
  doi = {10.1093/jbi/wbae053}
}
Kostenlos starten →